Starpharma HoldingsASX:SPL +0.72%53 Days Inventory is 817.97 as of Dec. 2025, which is 41% above its 10-year median of 580.22. GuruFocus rates ASX:SPL with a GF Score™ of 53/100 and a GF Value™ of A$0.43 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 639 Biotechnology companies, Starpharma Holdings ranks worse than 83.57% on this metric.
The historical rank and industry rank for Starpharma Holdings's Days Inventory or its related term are showing as below:
ASX:SPL'
s Days Inventory Range Over the Past 10 Years
Min: 183.12 Med: 580.22 Max: 1496.1
Current: 570.6
During the past 13 years, Starpharma Holdings's highest Days Inventory was 1496.10. The lowest was 183.12. And the median was 580.22.
ASX:SPL's Days Inventory is ranked worse than 83.57% of 639
companies
in the Biotechnology industry
Industry Median: 183.97
vs ASX:SPL: 570.60
Starpharma Holdings's Days Inventory
declined
from Dec. 2024 (1,241.31) to Dec. 2025 (817.97).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Starpharma Holdings's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.22.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Starpharma Holdings's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.17.
Starpharma Holdings (ASX:SPL) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Starpharma Holdings's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Starpharma Holdings's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Starpharma Holdings Days Inventory Related Terms
Starpharma Holdings Days Inventory Historical Data
* Premium members only.
The historical data trend for Starpharma Holdings's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:SPL vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Starpharma Holdings's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Starpharma Holdings Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Starpharma Holdings's Days Inventory distribution charts can be found below:
* The bar in red indicates where Starpharma Holdings's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Starpharma Holdings (ASX:SPL) has a Days Inventory of 817.97 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Starpharma Holdings and its competitors. This is 41% above median its historical median of 580.22. Over the past decade, Starpharma Holdings' Days Inventory has ranged from 183.12 to 1,496.10. According to the industry distribution chart, Starpharma Holdings ranks #534 out of 639 companies in the Biotechnology industry, placing it in the top 83.6%.
Is Starpharma Holdings' Days Inventory too high?
Starpharma Holdings' current Days Inventory of 817.97 is 41% above median its 10-year median of 580.22. Over the past 10 years, this metric has ranged from a low of 183.12 to a high of 1,496.10. The Biotechnology industry median Days Inventory is 183.97. Starpharma Holdings' value of 817.97 is 344.6% above this industry median. Based on the distribution chart, Starpharma Holdings ranks #534 out of 639 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Starpharma Holdings has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Starpharma Holdings' Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Starpharma Holdings ranks #534 out of 639 companies for Days Inventory. This places Starpharma Holdings in the lower half of its industry. The industry median Days Inventory is 183.97. Starpharma Holdings' value of 817.97 is 344.6% above this benchmark. Historically, Starpharma Holdings' own Days Inventory has ranged from 183.12 to 1,496.10 over the past decade. While the company's 10-year median is 580.22 vs. the industry median of 183.97, Starpharma Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.97, based on 639 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Starpharma Holdings's current Days Inventory of 817.97 is 344.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Starpharma Holdings and its competitors. For the Biotechnology industry, the median Days Inventory is 183.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Starpharma Holdings's current Days Inventory is 817.97, which is 41% above median its own 10-year median of 580.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starpharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Starpharma Holdings (ASX:SPL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.43, compared to a current price of A$0.70 — trading 61.6% above its estimated fair value. The current Days Inventory is 817.97, which is 41% above median its 10-year median of 580.22 and 344.6% above the Biotechnology industry median of 183.97. Starpharma Holdings' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Starpharma Holdings (ASX:SPL), the current Days Inventory is 817.97 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Starpharma Holdings (ASX:SPL) Overvalued in 2026?
Based on GuruFocus' analysis, Starpharma Holdings stock appears to be overvalued.
The current stock price of A$0.70 is trading 61.6% above its estimated GF Value™ of A$0.43.
GuruFocus considers Starpharma Holdings to be Significantly Overvalued.
Key valuation signals for ASX:SPL:
Days Inventory: 817.97 (41% above median its 10-year median of 580.22)
GF Value™: A$0.43 vs. price of A$0.70 (61.6% above fair value)
Industry Position: 344.6% above the Biotechnology median (#534 of 639)
No single metric tells the full story. See the ASX:SPL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
53GF Score
Get the complete analysis for ASX:SPL
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:SPL has been successfully added to your 
